MARKET NEWS

Cytel & Axio Join Forces to Create Industry Leader in Analytical Solutions for Drug Development
Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial
CURE Pharmaceutical & Canopy Growth to Produce CBD Oral Thin Films
Protalix BioTherapeutics Completes Enrollment in Phase 3 Trial
Catalent to Purchase Bristol-Myers Squibb Facility
Bavarian Nordic Initiates Phase 3 Trial of Vaccine

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Frontida BioPharm, Inc. is a leading provider of  product development and manufacturing services for both small and large biotech, pharmaceutical and consumer health companies. Combining the rich heritage of resources from URL/Mutual Pharmaceuticals in Philadelphia, PA, and Aurora, IL, with the development expertise from Frontage Laboratories and the region’s best pharmaceutical companies, Frontida is helping our partners reach the market faster, ensuring robust product performance and on-time supply of clinical and commercial products. Our 300,000-sq-ft manufacturing facilities supply prescription and OTC products, Highly Potent Active Ingredient (HPAI) products, Fixed-dose Combination Products, and DEA schedules II–V products. Our 4 commercial packaging lines, equipped with validated product serialization technology, provide packaging services for both commercial products and clinical trial material supplies. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Aclaris Therapeutics Announces Positive 6-Month Results from Phase 2  Clinical Trial

Aclaris Therapeutics Announces Positive 6-Month Results from Phase 2  Clinical Trial

Aclaris Therapeutics, Inc. recently announced positive results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor, in patients with androgenetic alopecia (AGA), a condition commonly known as male/female-pattern baldness.

Global DNA Sequencing: Research, Applied & Clinical Markets

Global DNA Sequencing: Research, Applied & Clinical Markets

The global sequencing market should grow from $10.7 billion in 2018 to $24.4 billion by 2023, with a compound annual growth rate (CAGR) of 18.0% for the period of 2018-2023.

iBio Announces First Agreement for Fill-Finish Services

iBio Announces First Agreement for Fill-Finish Services

iBio, Inc. recently announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies.

Gilead & Nurix Establish Lucrative Strategic Collaboration

Gilead & Nurix Establish Lucrative Strategic Collaboration

Gilead Sciences, Inc. and Nurix Therapeutics, Inc. recently announced a global strategic collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.

Sanofi & Google to Develop New Healthcare Innovation Lab

Sanofi & Google to Develop New Healthcare Innovation Lab

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies.

Array BioPharma Acquisition Will Accelerate Pfizer’s Position as a Major Player in Colorectal Cancer 

Array BioPharma Acquisition Will Accelerate Pfizer’s Position as a Major Player in Colorectal Cancer 

Following the news that Pfizer has agreed to acquire Array BioPharma in a deal worth approximately $11.4 billion, Tajekesa Chapman, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the potential of this buy-out on the treatment of colorectal cancers. 

IVERIC bio Enters Strategic Manufacturing Relationship With Catalent's Paragon Gene Therapy

IVERIC bio Enters Strategic Manufacturing Relationship With Catalent's Paragon Gene Therapy

IVERIC bio, Inc. and Catalent Biologics recently announced they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC bio’s gene therapy product candidates.

PHASTAR Enters Technology Partnership With Medidata

PHASTAR Enters Technology Partnership With Medidata

PHASTAR recently announced today it has entered into a technology partnership with Medidata Solutions, Inc. PHASTAR will deploy several solutions from the Medidata Rave Clinical Cloud, including Rave EDC, Coder, eCOA, and RTSM.

Kymab & LifeArc Enter Strategic Partnership to Discover New Medicines Using Kymab’s IntelliSelect Technologies

Kymab & LifeArc Enter Strategic Partnership to Discover New Medicines Using Kymab’s IntelliSelect Technologies

The agreement will enable LifeArc to enhance its antibody drug discovery capabilities into new medicinal products with Kymab’s proprietary IntelliSelect technology platforms.

PREMIA & AmoyDx Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network

PREMIA & AmoyDx Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network

Loxo Oncology, Inc. recently entered into a strategic partnership agreement with Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Ltd.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 10 – Prefilled Syringes
July 17 – Parenteral Contract Manufacturing